Medicago Planning Vaccine Production Facility in Durham, North Carolina
08/10/2010
"North Carolina's quality of work force, its training programs, and overall understanding of biotech development models were critical factors in our decision to locate in RTP," said Andy Sheldon, president and CEO of Medicago. "We are thrilled with our decision to build our vaccine facility in one of the largest and successful technology parks."
Medicago has received a $21 million research grant from the Defense Advanced Research Projects Agency (DARPA) to improve the production process of H1N1 vaccines. The company's project represents a total investment of more than $32 million in Research Triangle Park.
Most Read
-
-
A Site Selector’s Checklist for Locating in the U.S.
Location USA 2019
-
Where to Invest in the Booming Aerospace Manufacturing Industry
2019 Auto/Aero Site Guide
-
What Should High-Growth Companies Look for in a Community?
Q4 2019
-
A Changing Food Manufacturing Industry
2017 Food Processing
-
Front Line: Trend Toward Microfactories Continues
Q4 2019
-
33rd Annual Corporate Survey & the 15th Annual Consultants Survey
Q1 2019